Lasers for BPH
This article was originally published in The Gray Sheet
Executive Summary
FDA reiterates policy that lasers cannot be promoted for treatment of benign prostatic hypertrophy without agency clearance ("The Gray Sheet" Nov. 9, I&W-10) in a Jan. 14 letter to the American Urological Association. To date, no manufacturers have obtained clearance for BPH. In order to gain BPH clearance, manufacturers must conduct clinical trials under an investigational device exemption, FDA says. The agency tells AUA that it will not restrict individual practitioners' use of the devices for BPH; however, FDA emphasizes that its policy to not interfere with physicians' practice "should not be construed as an endorsement of [the BPH] procedure by FDA. Our position is that there are insufficient data at this point to establish the safety and effectiveness of lasers for this specific purpose"....
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.